文献速递银屑病与炎症性皮肤病

托法替布治疗中重度斑块状银屑病的系统评价与Meta分析

Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2017-12-05

该系统评价与Meta分析纳入4项随机对照试验共2724例中重度斑块状银屑病患者,评估托法替布的有效性与安全性。与安慰剂相比,托法替布5 mg和10 mg每日两次均显著改善PASI≥75%、PASI≥90%、PGA 0/1及DLQI 0/1,但上呼吸道感染和高胆固醇血症等轻微不良事件增加。

要点

  • 托法替布5 mg和10 mg每日两次均显著优于安慰剂改善中重度斑块状银屑病。
  • 10 mg每日两次在PASI≥75/90和PGA 0/1上的风险差高于5 mg每日两次。
  • 上呼吸道感染和高胆固醇血症等轻微不良事件风险轻度增加。

核心结论

  • 托法替布可能作为对其他治疗无应答、不耐受或偏好口服药物的中重度斑块状银屑病患者的治疗选择。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、Cochrane Central Register of Controlled Trials和EMBASE,纳入4项随机对照试验共2724例参与者。

主要发现

  • 与安慰剂相比,托法替布5 mg每日两次的PASI≥75风险差为0.32(95%CI 0.28-0.35),10 mg每日两次为0.51(95%CI 0.43-0.58)。
  • PASI≥90风险差:5 mg每日两次0.19(95%CI 0.17-0.22),10 mg每日两次0.36(95%CI 0.31-0.42)。
  • PGA 0/1风险差:5 mg每日两次0.31(95%CI 0.27-0.35),10 mg每日两次0.48(95%CI 0.44-0.53)。
  • DLQI 0/1风险差:5 mg每日两次0.24(95%CI 0.20-0.2),10 mg每日两次0.36(95%CI 0.33-0.40)。
  • 上呼吸道感染风险差:5 mg每日两次0.02(95%CI 0.00-0.03),10 mg每日两次0.02(95%CI 0.00-0.04);高胆固醇血症风险差:5 mg每日两次0.02(95%CI 0.01-0.04),10 mg每日两次0.02(95%CI 0.01-0.04)。

临床怎么用

  • 对于其他治疗无应答或不耐受、或偏好口服药物的中重度斑块状银屑病患者,可考虑托法替布治疗。
  • 使用托法替布时需关注上呼吸道感染和高胆固醇血症等轻微不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The effects of tofacitinib in treating moderate-to-severe plaque psoriasis were unclear. We aimed to assess the effects of tofacitinib in treating moderate-to-severe plaque psoriasis. We searched PubMed, Cochrane Central Register of Controlled Trials and EMBASE for relevant randomized controlled trials (RCTs) and conducted a systematic review and meta-analysis. Four RCTs with 2724 participants were included. Compared to placebo, tofacitinib significantly improved psoriasis {≥75% reduction in the Psoriasis Area and Severity Index score: 5 mg BID: risk difference (RD) 0.32 [95% confidence interval (CI) 0.28-0.35], 10 mg BID: RD 0.51 (95% CI 0.43-0.58); ≥90% reduction in the Psoriasis Area and Severity Index score: 5 mg BID: RD 0.19 (95% CI 0.17-0.22), 10 mg BID: RD 0.36 (95% CI 0.31-0.42); Physician's Global Assessment 0/1: 5 mg BID: RD 0.31 (95% CI 0.27-0.35), 10 mg BID: RD 0.48 (95% CI 0.44-0.53)} and participants' life quality [Dermatology Life Quality Index 0/1: 5 mg BID: RD 0.24 (95% CI 0.20-0.2), 10 mg BID: RD 0.36 (95% CI 0.33-0.40)]. Tofacitinib was associated with an increase in minor adverse events [upper respiratory tract infection: 5 mg BID: RD 0.02 (95% CI 0.00-0.03), 10 mg BID: RD 0.02 (95% CI 0.00-0.04); hypercholesterolaemia: 5 mg BID: RD 0.02 (95% CI 0.01-0.04), 10 mg BID: RD 0.02 (95% CI 0.01-0.04)]. In conclusion, tofacitinib may be a treatment option for moderate-to-severe plaque psoriasis that is unresponsive to other therapies and patients who are intolerable to other therapies or prefer oral medications.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Kuo CM, Tung TH, Wang SH, et al. Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2017. PMID: 29136293. doi:10.1111/jdv.14695

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。